Cantor Fitzgerald Maintains Overweight on Vanda Pharma, Raises Price Target to $13
Vanda Pharma Analyst Ratings
Cantor Fitzgerald Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Raises Target Price to $13
Vanda Pharma Analyst Ratings
Cantor Fitzgerald Initiates Coverage On Vanda Pharma With Overweight Rating, Announces Price Target of $11